论文部分内容阅读
目的:观察柴葛口服液(II)对四氯化碳肝纤维化大鼠体内模型的作用。方法:采用皮下注射四氯化碳诱导Wistar大鼠肝纤维化动物模型后,每天灌胃给予PO柴葛口服液(II)0.4mL.kg-1.d-1至第12周,酶动力学法检测分析肝功能,放射免疫分析法测定透明质胶(HA)、III型前胶原(PCIII)、层黏连蛋白(LN)、IV型胶原(IVC)等血清肝纤维化标志物指标,SP免疫组化法检测肝组织中α-肌动蛋白(α-SMA)、转化生长因子β1(TGF-β1)表达的影响,用苏木精-伊红染色(HE)和胶原纤维染色观察大鼠肝脏病理变化。结果:10周后,治疗组与模型组ALT、AST、MAO及HA、PC III、LN、IV-C等指标相比差异有显著性(P<0.05),并且治疗组肝组织纤维化程度分级较模型组逐渐好转,胶原纤维所占面积显著缩小;α-SMA和TGF-β1在治疗组和模型组肝组织中的表达差异也有显著性(P<0.01)。结论:柴葛口服液(II)能有效保护肝细胞,减轻肝纤维化。
OBJECTIVE: To observe the effect of Chaige Oral Liquid (II) on in vivo models of carbon tetrachloride in rats with hepatic fibrosis. METHODS: After subcutaneous injection of carbon tetrachloride to induce Wistar rat liver fibrosis animal models, PO Chaige Oral Solution (II) 0.4 mL.kg-1.d-1 was given to the 12th week by intragastric administration. Liver function was determined by assay and radioimmunoassay. Serum markers of liver fibrosis such as hyaluronan (HA), type III procollagen (PCIII), laminin (LN), and type IV collagen (IVC) were measured. SP Immunohistochemistry was used to examine the effects of α-SMA and transforming growth factor β1 (TGF-β1) expression in liver tissue. Rats were observed with hematoxylin-eosin staining (HE) and collagen fiber staining. Liver pathological changes. Results: After 10 weeks, there was significant difference in ALT, AST, MAO and HA, PC III, LN, IV-C between the treatment group and the model group (P<0.05), and the degree of hepatic fibrosis was graded in the treatment group. Compared with the model group, the area occupied by collagen fibers was significantly reduced; the expression of α-SMA and TGF-β1 in the liver tissue of the treatment group and the model group also had significant differences (P<0.01). Conclusion: Chaige Oral Liquid (II) can effectively protect liver cells and reduce liver fibrosis.